13F Holdings
中文EN

ELUT ELUTIA INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1708527 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.2%
TTM net income YoY305.5%
TTM EPS YoY233.3%
Revenue 3-yr CAGR-26.9%
Net income 3-yr CAGR—

Margins

Gross margin59.0%
Operating margin-279.0%
Net margin546.7%
FCF margin-509.4%
EBITDA margin-265.2%

Returns

ROE—
ROA140.2%
ROIC (approx.)—
Asset turnover0.26x

Leverage & solvency

Liabilities / assets68.2%
Debt / equity0.53x
Current ratio2.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.91x
Accruals ratio267.1%
Payout ratio—
Capex / revenue14.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$12.29M$14.47M$24.75M$23.85M$47.39M
Cost of revenue$5.70M$7.75M$13.69M$12.21M$28.37M
Gross profit$6.60M$6.71M$11.05M$11.64M$19.02M
R&D expense$4.16M$3.00M$4.40M$7.73M$9.27M
SG&A expense$15.08M$18.07M$14.10M$16.05M$13.69M
Operating income-$26.91M-$30.71M-$30.53M-$35.19M-$23.03M
Interest expense—$4.78M$5.80M$5.12M$5.32M
Pretax income-$15.86M-$45.34M-$41.22M-$36.15M-$24.78M
Income tax$13,000$7,000$28,000$34,000$55,000
Net income$53.38M-$53.95M-$37.66M-$32.90M-$24.83M
EBITDA-$24.13M-$27.26M-$26.78M-$31.46M-$19.30M
EPS (basic)1.29-1.86-2.07-2.38-2.38
EPS (diluted)0.87-1.86-2.07-2.38-2.38
Weighted avg. shares (diluted)45.94M29.07M18.16M13.83M10.44M
Balance sheet
Cash & equivalents$36.35M$13.24M$19.28M$16.99M$30.43M
Receivables$1.73M$2.28M$3.26M$3.77M$6.00M
Inventory$438,000$1.93M$3.85M$4.24M$9.55M
Current assets$55.82M$26.17M$31.25M$50.70M$47.43M
PP&E, net$2.51M$671,000$172,000$245,000$1.20M
Intangibles$1.53M$2.60M$11.67M$15.07M$18.47M
Total assets$62.35M$36.13M$43.43M$68.84M$67.17M
Current liabilities$25.14M$37.80M$43.04M$42.62M$26.00M
Short-term debt—$1.25M$3.32M—$8.06M
Long-term debt—$22.60M$20.36M$24.26M$10.41M
Total debt—$23.85M$23.68M$24.26M$18.47M
Total liabilities$34.68M$82.39M$82.03M$73.87M$53.65M
Shareholders' equity$27.67M-$46.26M-$38.60M-$5.03M$13.52M
Net debt—$10.61M$4.40M$7.27M-$11.96M
Cash flow statement
Operating cash flow-$44.81M-$22.66M-$21.76M-$21.43M-$15.45M
Capital expenditure$1.88M$654,000$346,000$540,000$369,000
Free cash flow-$46.69M-$23.31M-$22.11M-$21.97M-$15.81M
Investing cash flow$78.56M-$474,000$14.21M-$540,000-$369,000
Financing cash flow-$10.64M$17.09M$9.84M$8.54M$6.71M
Depreciation & amortization$2.79M$3.45M$3.75M$3.73M$3.73M
Stock-based compensation$5.21M$7.89M$2.44M$3.65M$3.54M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.